SEARCH

SEARCH BY CITATION

References

  • 1
    Neumiller JJ, Wood L & Campbell RK (2010) Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 30, 463484.
  • 2
    Piya MK, Tahrani AA & Barnett AH (2010) Emerging treatment options for type 2 diabetes. Br J Clin Pharmacol 70, 631644.
  • 3
    Yu DMT, Yao T-W, Chowdhury S, Nadvi NA, Osborne B, Church WB, McCaughan GW & Gorrell MD (2010) The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 277, 11261144.
  • 4
    Gorrell MD, Song S & Wang XM (2010) Novel metabolic disease therapy. International patent application 2010/083570.
  • 5
    Levy MT, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Muller E, Rettig WJ & Gorrell MD (1999) Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 29, 17681778.
  • 6
    Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA & Fearon DT (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α. Science 330, 827830.
  • 7
    Heymann E & Mentlein R (1978) Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. FEBS Lett 91, 360364.
  • 8
    Mentlein R, Gallwitz B & Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214, 829835.
  • 9
    Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ & Rettig WJ (1999) Fibroblast activation protein: a dual-specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 274, 3650536512.
  • 10
    Yu DMT, Ajami K, Gall MG, Park J, Lee CS, Evans KA, McLaughlin EA, Pitman MR, Abbott CA, McCaughan GW et al. (2009) The in vivo expression of dipeptidyl peptidases 8 and 9. J Histochem Cytochem 57, 10251040.
  • 11
    Lee KN, Jackson KW, Christiansen VJ, Chung KH & McKee PA (2004) A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood 103, 37833788.
  • 12
    Aertgeerts K, Levin I, Shi L, Snell GP, Jennings A, Prasad GS, Zhang Y, Kraus ML, Salakian S, Sridhar V et al. (2005) Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem 280, 1944119444.
  • 13
    Edosada CY, Quan C, Tran T, Pham V, Wiesmann C, Fairbrother W & Wolf BB (2006) Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. FEBS Lett 580, 15811586.
  • 14
    Christiansen VJ, Jackson KW, Lee KN & McKee PA (2007) Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch Biochem Biophys 457, 177186.
  • 15
    Bellemere G, Vaudry H, Morain P & Jegou S (2005) Effect of prolyl endopeptidase inhibition on arginine-vasopressin and thyrotrophin-releasing hormone catabolism in the rat brain. J Neuroendocrinol 17, 306313.
  • 16
    Aertgeerts K, Ye S, Tennant MG, Kraus ML, Rogers J, Sang BC, Skene RJ, Webb DR & Prasad GS (2004) Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci 13, 412421.
  • 17
    Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG & McKee PA (2006) Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 107, 13971404.
  • 18
    Garin-Chesa P, Old LJ & Rettig WJ (1990) Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 87, 72357239.
  • 19
    Wang XM, Yu DMT, McCaughan GW & Gorrell MD (2005) Fibroblast activation protein increases apoptosis, cell adhesion and migration by the LX-2 human stellate cell line. Hepatology 42, 935945.
  • 20
    Wolf BB, Quan C, Tran T, Wiesmann C & Sutherlin D (2008) On the edge of validation – cancer protease fibroblast activation protein. Mini Rev Med Chem 8, 719727.
  • 21
    Pure E (2009) The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer. Expert Opin Ther Targets 13, 967973.
  • 22
    Santos AM, Jung J, Aziz N, Kissil JL & Pure E (2009) Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 119, 36133625.
  • 23
    Wang XM, Yao T-W, Nadvi NA, Osborne B, McCaughan GW & Gorrell MD (2008) Fibroblast activation protein and chronic liver disease. Front Biosci 13, 31683180.
  • 24
    Thornberry NA & Gallwitz B (2009) Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 23, 479486.
  • 25
    Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, Schmidt K, Bagchi A, Griffin PR, Thornberry NA et al. (2003) The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1–38). J Biol Chem 278, 2241822423.
  • 26
    Lambeir AM, Durinx C, Proost P, Van Damme J, Scharpe S & De Meester I (2001) Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett 507, 327330.
  • 27
    Deacon CF, Johnsen AH & Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80, 952957.
  • 28
    Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S & Brubaker PL (1997) Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 15, 673677.
  • 29
    Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB & Holst JJ (2000) In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 85, 28842888.
  • 30
    Kieffer TJ, McIntosh CH & Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136, 35853596.
  • 31
    Deacon CF, Danielsen P, Klarskov L, Olesen M & Holst JJ (2001) Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 50, 15881597.
  • 32
    Otsuka M & Yoshioka K (1993) Neurotransmitter functions of mammalian tachykinins. Physiol Rev 73, 229308.
  • 33
    Sudoh T, Minamino N, Kangawa K & Matsuo H (1988) Brain natriuretic peptide-32: N-terminal six amino acid extended form of brain natriuretic peptide identified in porcine brain. Biochem Biophys Res Commun 155, 726732.
  • 34
    Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpe S & De Meester I (2006) Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 52, 8287.
  • 35
    Mentlein R, Dahms P, Grandt D & Kruger R (1993) Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49, 133144.
  • 36
    Shioda T, Kato H, Ohnishi Y, Tashiro K, Ikegawa M, Nakayama EE, Hu H, Kato A, Sakai Y, Liu H et al. (1998) Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci USA 95, 63316336.
  • 37
    Lambeir AM, Proost P, Durinx C, Bal G, Senten K, Augustyns K, Scharpe S, Van Damme J & De Meester I (2001) Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 276, 2983929845.
  • 38
    Proost P, Menten P, Struyf S, Schutyser E, De Meester I & Van Damme J (2000) Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood 96, 16741680.
  • 39
    Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E & Norcross MA (1997) Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation normal T cell expressed and activated) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 186, 18651872.
  • 40
    Ajami K, Pitman MR, Wilson CH, Park J, Menz RI, Starr AE, Cox JH, Abbott CA, Overall CM & Gorrell MD (2008) Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett 582, 819825.
  • 41
    Edosada CY, Quan C, Wiesmann C, Tran T, Sutherlin D, Reynolds M, Elliott JM, Raab H, Fairbrother W & Wolf BB (2006) Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J Biol Chem 281, 74377444.
  • 42
    Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, Cotter RJ & Denmeade SR (2008) Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry 47, 10761086.
  • 43
    Hoffmann T, Faust J, Neubert K & Ansorge S (1993) Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett 336, 6164.
  • 44
    Bongers J, Lambros T, Ahmad M & Heimer EP (1992) Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim Biophys Acta 1122, 147153.
  • 45
    Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD, Lee EW, Burnett MS, Fricke ST, Kvetnansky R et al. (2007) Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 13, 803811.
  • 46
    Zukowska Z, Pons J, Lee EW & Li L (2003) Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system? Can J Physiol Pharmacol 81, 8994.
  • 47
    Federico C (2010) Natriuretic peptide system and cardiovascular disease. Heart Views 11, 1015.
  • 48
    Sonoyama T, Tamura N, Miyashita K, Park K, Oyamada N, Taura D, Inuzuka M, Fukunaga Y, Sone M & Nakao K (2009) Inhibition of hepatic damage and liver fibrosis by brain natriuretic peptide. FEBS Lett 583, 20672070.
  • 49
    Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM & Burnett JC Jr (2007) Immunoreactivity and guanosine 3′,5′-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 49, 11141119.
  • 50
    Cox HM, Tough IR, Woolston A-M, Zhang L, Nguyen AD, Sainsbury A & Herzog H (2010) Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses. Cell Metab 11, 532542.
  • 51
    Timmer JC, Enoksson M, Wildfang E, Zhu W, Igarashi Y, Denault JB, Ma Y, Dummitt B, Chang YH, Mast AE et al. (2007) Profiling constitutive proteolytic events in vivo. Biochem J 407, 4148.
  • 52
    Levy MT, McCaughan GW, Marinos G & Gorrell MD (2002) Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver 22, 93101.
  • 53
    Cassiman D, Denef C, Desmet VJ & Roskams T (2001) Human and rat hepatic stellate cells express neurotrophins and neurotrophin receptors. Hepatology 33, 148158.
  • 54
    Esteban FJ, Jimenez A, Fernandez AP, del Moral ML, Sanchez-Lopez AM, Hernandez R, Garrosa M, Pedrosa JA, Rodrigo J & Peinado MA (2001) Neuronal nitric oxide synthase immunoreactivity in the guinea-pig liver: distribution and colocalization with neuropeptide Y and calcitonin gene-related peptide. Liver 21, 374379.
  • 55
    Ding WG, Kitasato H & Kimura H (1997) Development of neuropeptide Y innervation in the liver. Microsc Res Tech 39, 365371.
  • 56
    Park J, Knott HM, Nadvi NA, Collyer CA, Wang XM, Church WB & Gorrell MD (2008) Reversible inactivation of human dipeptidyl peptidases 8 and 9 by oxidation. Open Enzym Inhib J 1, 5261.